Pivotal Phase 3 results for relugolix combination therapy in patients with endometriosis-associated pain were published on 2022-01-01. The publication detailed the efficacy and safety of once-daily oral relugolix combination therapy compared to placebo for this condition.
Background
This publication concerns relugolix combination therapy, which includes relugolix, estradiol hemihydrate, and norethindrone acetate. The therapy was investigated for its potential in managing pain associated with endometriosis.
Trial design
The published results are from two replicate Phase 3, randomized, double-blind studies, including the SPIRIT 2 study, which evaluated the efficacy and safety of relugolix combination therapy. These studies compared once-daily oral relugolix combination therapy against placebo in patients experiencing endometriosis-associated pain.
What this means
The publication of these pivotal Phase 3 results for relugolix combination therapy provides important data regarding its efficacy and safety profile for patients with endometriosis-associated pain. Clinicians and researchers can now review the detailed findings from these randomized, double-blind studies to understand the potential role of this once-daily oral therapy in managing the condition.
Source
Information regarding the publication of these trial results was obtained from PubMed, a database of biomedical literature. The article, titled "Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, st", was published on 2022-01-01 and is accessible via pubmed.ncbi.nlm.nih.gov.